Interleukin-17A: A Potential Therapeutic Target in Chronic Lung Diseases

Jan 18, 2019Endocrine, metabolic & immune disorders drug targets

Interleukin-17A as a Possible Treatment Target in Long-Term Lung Diseases

AI simplified

Abstract

Interleukin-17A (IL-17A) is identified as a significant factor in various chronic respiratory diseases.

  • IL-17A is involved in immune responses related to allergy and inflammation.
  • The cytokine is linked to the progression of conditions such as Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disease (COPD), asthma, pneumonia, and lung cancer.
  • Increased levels of IL-17A may contribute to the severity of these respiratory diseases.
  • Conversely, the absence of IL-17A could lead to a reduction in disease severity.
  • The review highlights IL-17A as a potential target for therapeutic intervention in chronic respiratory conditions.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free